Human induced pluripotent stem cell-derived ovarian support cell co-culture improves oocyte maturation in vitro after abbreviated gonadotropin stimulation

Sabrina Piechota, Maria Marchante, Alexa Giovannini, Bruna Paulsen, Kathryn Potts, Graham Rockwell, Caroline Aschenberger, Alexander D Noblett, Alexandra B Figueroa, Marta Sanchez, Ferran Barrachina, Klaus Wiemer, Luis Guzmán, Pedro Belchin, Merrick Pierson Smela, Patrick R.j. Fortuna, Pranam Chatterjee, Nam D. Tran, Dawn A. Kelk, Marcy Forti, Shelby Marcinyshyn, Trozalla Smith, David H. McCulloh, Marta-Julia Fernandez-Gonzalez, Silvia Ortiz, Joshua U. Klein, Peter Klatsky, Daniel Ordonez-Perez, Christian KrammebioRxiv 2023 · DOI

TL;DR

This study introduces a novel in vitro maturation (IVM) system using ovarian support cells (OSCs) derived from human induced pluripotent stem cells (hiPSCs). This OSC-IVM approach significantly improves the maturation rate of immature human oocytes and leads to a higher rate of healthy, euploid blastocyst formation compared to existing IVM methods, offering a promising advancement for fertility treatments.

What Problem Does This Paper Address?

Infertility affects a significant portion of the population, and assisted reproductive technologies (ART) like IVF and IVM are crucial for treatment. While IVM offers an alternative to conventional ovarian stimulation (COS), it has historically suffered from variable success rates and lower developmental potential of the resulting oocytes. Current IVM methods often struggle to produce oocytes with robust developmental capacity, and some newer approaches are limited to non-standard protocols. This paper addresses the need for a more effective and reliable IVM system that can yield high-quality oocytes, particularly from abbreviated stimulation cycles, which are often preferred for their reduced cost and side effects.

Methods

The core innovation in this study is the development and application of an in vitro maturation (IVM) system co-cultured with human induced pluripotent stem cell-derived ovarian support cells (hiPSC-OSCs). These OSCs were generated through a transcription factor-directed protocol and mimic natural ovarian granulosa cells.

The study involved three main experimental comparisons:

  1. OSC Activity: To determine if the OSCs themselves were the active component in improving maturation, comparing OSC-IVM to media alone or media with other cell types (fetal ovarian somatic cells - FOSCs).
  2. OSC Clinical Relevance (IVM only): To compare the efficacy of the OSC-IVM system against a commercially available IVM medium (Medicult IVM) for oocyte maturation.
  3. OSC Clinical Relevance (Embryo Formation): To assess the developmental competence of oocytes matured using OSC-IVM by evaluating fertilization, cleavage, blastocyst formation, and euploidy rates compared to the commercial IVM control.

Immature oocytes were retrieved from donors undergoing abbreviated gonadotropin stimulation. These oocytes were then cultured in either the OSC-IVM system or control conditions. Maturation rates (Metaphase II - MII), oocyte morphology (Total Oocyte Score - TOS), fertilization, cleavage, blastocyst formation, and preimplantation genetic testing for aneuploidy (PGT-A) were assessed. Additionally, the epigenetic profiles of resulting blastocysts were analyzed.

Datasets

The study utilized oocytes retrieved from 67 human oocyte donors aged 19-37 years, recruited from multiple fertility clinics. For embryo epigenetic analysis, five euploid blastocysts generated from the OSC-IVM condition were compared with eight donated euploid blastocysts from conventional controlled ovarian stimulation (COS) cycles. External reference data from previous studies on COS and CAPA-IVM (another IVM approach) were also used for epigenetic comparisons. No new benchmarks were introduced; rather, existing metrics and established protocols were used for evaluation.

Key Insights and Ideas

  • hiPSC-derived OSCs are potent enhancers of oocyte maturation: The study clearly demonstrates that co-culturing immature oocytes with hiPSC-derived OSCs significantly boosts the rate at which they reach the mature MII stage. This suggests that OSCs provide crucial signals that promote nuclear and cytoplasmic maturation.
  • Beyond maturation: improved developmental potential: The OSC-IVM system not only improves oocyte maturation but also leads to a higher rate of euploid blastocyst formation. This indicates that the matured oocytes are more developmentally competent and capable of forming healthy embryos.
  • Epigenetic normalcy: Crucially, blastocysts derived from OSC-IVM show normal global and germline epigenetic profiles, comparable to those from conventional COS. This is a key indicator of their potential for healthy development and implantation, addressing a critical concern for IVM-derived embryos.
  • Scalability and broad applicability: The OSC-IVM approach integrates well with existing ART laboratory procedures and uses a single source of hiPSCs, suggesting it is scalable, reproducible, and cost-effective, making it a promising candidate for widespread clinical adoption.
  • Specificity of OSCs: The study suggests that the benefit comes from the engineered granulosa-like cells themselves, not just the general co-culture environment or other cell types like FOSCs.

Key Results

  • MII Maturation Rate: OSC-IVM significantly improved MII formation rates by approximately 1.5x compared to media controls and commercially available IVM media. For instance, in Experiment 2, OSC-IVM achieved a 68% MII rate compared to 43% for commercial IVM (p=0.0349).
  • Euploid Blastocyst Formation: OSC-IVM showed a statistically significant improvement in euploid day 5 or 6 blastocyst formation, with rates of 25% ± 7.5% compared to 11% ± 3.7% for the commercial IVM control (p=0.0349).
  • Oocyte Morphology: While maturation rates improved, oocyte morphological quality (assessed by Total Oocyte Score) did not significantly differ between OSC-IVM and control groups, indicating no detrimental effect on quality.
  • Epigenetic Profile: Blastocysts generated via OSC-IVM exhibited similar global and germline methylation profiles to those from conventional COS, suggesting normal epigenetic development.

Limitations and Future Work

  • Basic Research Study: The authors acknowledge that the study's nature as a basic research study limits generalizability, and future randomized clinical trials are needed to establish the approach's clinical value.
  • Oocyte Maturation State: Due to the use of abbreviated stimulation cycles, the precise initial maturation state of oocytes prior to IVM could not be empirically assessed while preserving cumulus-oocyte connections.
  • Sample Size: While efforts were made for equitable distribution, slight imbalances in GV/MI/MII input distribution and overall small sample sizes in some comparisons are noted as limitations. Larger studies are recommended.
  • Mechanism of Action: Further research is needed to precisely determine the mechanism by which OSCs promote IVM, including identifying specific secreted factors and environmental changes.
  • Clinical Utility Validation: The ultimate validation of the approach's clinical utility will be its ability to generate healthy live births, which requires further clinical evaluation.
  • Comparison to Other IVM: While OSC-IVM showed promise, direct comparisons with other advanced IVM techniques like CAPA-IVM were not performed in this study, and future work could explore these differences.

Summary updated

Abstract

Abstract Assisted reproductive technologies (ART) have significantly impacted fertility treatment worldwide through innovations such as in vitro fertilization (IVF) and in vitro maturation (IVM). IVM holds promise as a technology for fertility treatment in women who cannot or do not wish to undergo conventional controlled ovarian stimulation (COS). However, IVM has historically shown highly variable performance in maturing oocytes and generating oocytes with strong developmental capacity. Furthermore, recently reported novel IVM approaches are limited to use in cycles lacking human chorionic gonadotropin (hCG) triggers, which is not standard practice in fertility treatment. We recently reported the development of ovarian support cells (OSCs) generated from human induced pluripotent stem cells (hiPSCs) that recapitulate dynamic ovarian function in vitro . Here we investigate the potential of the se OSCs in an IVM co-culture system to improve the maturation of human cumulus-enclosed immature oocytes retrieved from abbreviated gonadotropin stimulated cycles. We reveal that OSC-IVM significantly improves maturation rates compared to existing IVM systems. Most importantly, we demonstrate that OSC-assisted IVM oocytes are capable of significantly improving euploid blastocyst formation and yielding blastocysts with normal global and germline differential methylation region methylation profiles, a key marker of their clinical utility. Together, these findings demonstrate a novel approach to IVM with broad applicability to modern ART practice. Structured Abstract Objective To determine if in vitro maturation (IVM) of human oocytes can be improved by co-culture with ovarian support cells (OSCs) derived from human induced pluripotent stem cells (hiPSCs). Design Three independent experiments were performed in which oocyte donors were recruited to undergo abbreviated gonadotropin stimulation and retrieved cumulus oocyte complexes (COCs) were randomly allocated between the OSC-IVM and control IVM conditions. Subjects Across the three experiments, a total of 67 oocyte donors aged 19 to 37 years were recruited for retrieval using informed consent. Anti-mullerian hormone (AMH) value, antral follicle count (AFC), age, BMI, and ovarian pathology were used for inclusion and exclusion criteria. Intervention and Control The OSC-IVM culture condition was composed of 100,000 OSCs in suspension culture supplemented with human chorionic gonadotropin (hCG), recombinant follicle stimulating hormone (rFSH), androstenedione and doxycycline. IVM controls comprised commercially-available IVM media without OSCs and contained either the same supplementation as above (media-matched control), or FSH and hCG only (IVM media control). In one experiment, an additional control using fetal ovarian somatic cells (FOSCs) was used with the same cell number and media conditions as in the OSC-IVM. Main Outcome Measures Primary endpoints consisted of metaphase II (MII) formation rate and oocyte morphological quality assessment. A limited cohort of oocytes were utilized for secondary endpoints, consisting of fertilization and blastocyst formation rates with preimplantation genetic testing for aneuploidy (PGT-A) and embryo epigenetic analysis. Results OSC-IVM resulted in a statistically significant improvement in MII formation rate compared to the media-matched control, a commercially available IVM media control, and the FOSC-IVM control. Oocyte morphological quality between OSC-IVM and controls did not significantly differ. OSC-IVM displayed a trend towards improved fertilization, cleavage, and blastocyst formation. OSC-IVM showed statistically significant improvement in euploid day 5 or 6 blastocyst formation compared to the commercially available IVM media control. OSC-IVM embryos displayed similar epigenetic global and germline loci profiles compared to conventional stimulation and IVM embryos. Conclusion The novel OSC-IVM platform is an effective tool for maturation of human oocytes obtained from abbreviated gonadotropin stimulation cycles, supporting/inducing robust euploid blastocyst formation. OSC-IVM shows broad utility with different stimulation regimens, including hCG triggered and untriggered oocyte retrieval cycles, making it a highly useful tool for modern fertility treatment.
BibTeX
@misc{piechota2023human,
  author = {Sabrina Piechota and Maria Marchante and Alexa Giovannini and Bruna Paulsen and Kathryn Potts and Graham Rockwell and Caroline Aschenberger and Alexander D Noblett and Alexandra B Figueroa and Marta Sanchez and Ferran Barrachina and Klaus Wiemer and Luis Guzmán and Pedro Belchin and Merrick Pierson Smela and Patrick R.J. Fortuna and Pranam Chatterjee and Nam D. Tran and Dawn A. Kelk and Marcy Forti and Shelby Marcinyshyn and Trozalla Smith and David H. McCulloh and Marta-Julia Fernandez-Gonzalez and Silvia Ortiz and Joshua U. Klein and Peter Klatsky and Daniel Ordonez-Perez and Christian Kramme},
  title = {{Human induced pluripotent stem cell-derived ovarian support cell co-culture improves oocyte maturation <i>in vitro</i> after abbreviated gonadotropin stimulation}},
  year = {2023},
  doi = {10.1101/2023.03.27.534479},
  howpublished = {bioRxiv},
}

Loading related content...

Figure